B8FK: Biofrontera AG - Summary | Jitta

Biofrontera AG

DEU:B8FK

Price
€2.40
Loss Chance
54.1%
2.52JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
475 / 548
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (39)
Recent Business Performance (74)
Financial Strength (34)
Return to Shareholders (0)
Competitive Advantage (35)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 100.00% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
2.52
100.00%
4.52
82.89%
4.17
65.16%
Pharmaceuticals
3.43
100.00%
3.43
33.86%
5.32
55.98%
COMPANY DESCRIPTION
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.